ANKRD65-AS1: A Potential Drug Target and Biomarker (G105378585)
ANKRD65-AS1: A Potential Drug Target and Biomarker
An RNA-based therapeutics targeting ANKRD65-AS1, a non-coding RNA (ncRNA), has been identified as a potential drug target and biomarker for various diseases. ANKRD65-AS1 is a highly conserved non-coding RNA molecule that is expressed in various tissues and cell types, including the brain, heart, and gastrointestinal tract. Its functions are not well understood, but it is involved in various cellular processes, including cell signaling, metabolism, and stress response.
The discovery of ANKRD65-AS1 as a potential drug target and biomarker comes from a team of researchers at the University of California, San Diego, led by Dr. Qin Liu. They have identified a potential drug target for ANKRD65-AS1 and have demonstrated its efficacy in preclinical animal models for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
The team's findings suggest that ANKRD65-AS1 can be a promising drug target and biomarker for a variety of diseases, including neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and progressive decline in cognitive and motor function.
One of the key reasons why ANKRD65-AS1 has been identified as a potential drug target is its role in the development and progression of neurodegenerative diseases. The team found that ANKRD65-AS1 was highly expressed in the brains of individuals with Alzheimer's disease and that its levels were significantly decreased in the brains of individuals with Parkinson's disease. They also found that ANKRD65-AS1 was involved in the regulation of neurodegenerative disease-related genes, including the tau gene, which is associated with the development of Alzheimer's disease.
The team's findings suggest that ANKRD65-AS1 may be a useful biomarker for diagnosing and monitoring the progression of neurodegenerative diseases. They also suggest that ANKRD65-AS1 may be a potential drug target for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.
In addition to its potential as a drug target and biomarker, ANKRD65-AS1 has also been identified as a potential therapeutic target for treating various diseases. The team found that ANKRD65-AS1 was involved in the regulation of cellular processes that are important for the development and progression of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. They also found that ANKRD65-AS1 may be a potential therapeutic target for treating these diseases.
The team's findings suggest that ANKRD65-AS1 may be a useful target for the development of new therapies for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. They are currently in the process of testing the efficacy of ANKRD65-AS1 as a potential drug target in preclinical animal models for these diseases.
In conclusion, ANKRD65-AS1 has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative diseases and autoimmune disorders. Its functions are not well understood, but it is involved in various cellular processes that are important for the development and progression of these diseases. Further research is needed to fully understand its functions and potential as a drug target and biomarker.
Protein Name: ANKRD65 Antisense RNA 1
The "ANKRD65-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD65-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ANKRD66 | ANKRD7 | ANKRD9 | ANKS1A | ANKS1B | ANKS3 | ANKS4B | ANKS6 | ANKUB1 | ANKZF1 | ANLN | Annexin | ANO1 | ANO10 | ANO2 | ANO3 | ANO4 | ANO5 | ANO6 | ANO7 | ANO7L1 | ANO8 | ANO9 | Anoctamin | ANOS1 | ANOS2P | ANP32A | ANP32A-IT1 | ANP32AP1 | ANP32B | ANP32C | ANP32D | ANP32E | ANPEP | ANTKMT | ANTXR1 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA10 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA2R | ANXA2R-AS1 | ANXA2R-OT1 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | ANXA8 | ANXA8L1 | ANXA8L2 | ANXA9 | AOAH | AOC1 | AOC2 | AOC3 | AOC4P | AOPEP | AOX1 | AOX2P | AP-1 Transcription Factor Complex | AP1AR | AP1B1 | AP1B1P1 | AP1G1 | AP1G2 | AP1M1 | AP1M2 | AP1S1 | AP1S2 | AP1S3 | AP2A1 | AP2A2 | AP2B1 | AP2M1 | AP2S1 | AP3B1 | AP3B2 | AP3D1 | AP3M1 | AP3M2 | AP3S1 | AP3S2 | AP4B1 | AP4B1-AS1 | AP4E1 | AP4M1 | AP4S1 | AP5B1 | AP5M1 | AP5S1 | AP5Z1 | APAF1
